`
`PROPOSAL/PROTOCOL
`
`I. GOALS:
`
`The main objective of this pilot study is to demonstrate the
`feasibility of percutaneously placed aortic valve. This study is
`designed to show that such a device can be placed without the
`need for a sternotomy or circulatory bypass.
`
`II. HYPOTHESES:
`
`LWe speculate that we can disperse the forces that are
`required to seat an artificial aortic valve utilizing stent
`technology.
`2. We speculate that this procedure can be done safely and
`effectively utilizing percutaneous technologies.
`3. We speculate that the ascending aorta can withstand a
`stented structure without dissection or rupture.
`4. We speculate that the intraluminal valves can properly
`function within a stented system
`
`Ill. Equipment and Supplies
`1. We propose that we use 10 pigs to place the percutaneous
`devices and to derive the needed data. This would require
`the facilities to house and. provide upkeep. Our
`veterinarian facilities have these capabilities. Moreover,
`the facility has a catheterization laboratory which can be
`utilized with proper funding to derive the primary set of
`data. The collaborators and i will perform the procedures
`and interpretation necessary to publish our series. There
`will be a need for computers and software for the analysis.
`2. We will be making the valves and stents at the University
`of Missouri unless it is found that we have neither the
`
`expertise nor equipment. Thus far we have found our
`chemical engineering department invaluable in this area.
`
`NORRED EXHIBIT 2037 - Page 1
`Medtronic, Inc., Medtronic Vascular, Inc.,
`& Medtronic Corevalve, LLC
`
`v. Troy R. Norred, MD.
`Case |PR2014-00110
`
`
`
`Therefore, much of the expense will logically be in the
`development of the prototypes. The materials will.
`include, but will not be limited, to different polymers,
`metals, and ceramics to initiate in a fluid model the exact
`valves we will pursue in the animal. models. We estimate
`that the first 10 weeks of research will be the construction
`
`of adequate prototypes.
`3. it is invaluable to have adequate visualization of the aortic
`valve for the successful completion of this project, and in
`pursuit of this visualization we will utilize to an extent not
`previously utilized, echocardiography. We will place, as
`will be discussed in the procedures section, 3 echoprobes
`for the adequate visualization of the aortic valve. These
`will be placed in the esophagus, the right atrium, and
`transcutaneously. Also, an intravascular ultrasound will
`be utilized in the data acquisition. portion of the study.
`This could represent a substantial portion of our budget in
`securing these devices.
`4. We will. also be developing and modifying known
`catheters and peripheral equipment as seen necessary for
`the successful completion of this project. Excitingly, this
`may lead to a multitude of novel devices, which will be
`needed to visualize and deliver the stem/valve. Further,
`there will be the need for novel debulking devices to
`percutaneously (please see submitted background material
`for further explanation) remove the native aortic valve
`structure sufficiently to relieve the stenosis. This may
`require testing on a delivery device for precise biotome
`resection, percutaneous ultrasound and laser debulking
`and new more effective balloon valvuloplasty. However,
`debulking devices would not be necessary in this protocol
`because the pigs would not have aortic stenosis.
`5. Finally, staff will be instrumental in the timely completion
`of this project. These will include maintenance staff for
`the pigs as well as catheterization personnel. The
`
`NORRED EXHIBIT 2037 - Page 2
`
`
`
`engineering department will need partial fimding for post»
`doctoral candidates to help in the development of the
`valve. As well, the cardiology department and I will need
`secretarial support to help in the clerical and
`organizational demands placed upon a rigorous study
`protocol. This staff is fortunately available with a high
`level of experience within this institution and would only
`need allocation of said monies to properly establish their
`work roles.
`
`1V.
`
`COLLABORATION
`
`This project will be a multidiscipline effort including the
`collaborative efforts of representatives from the
`Cardiology, Biophysics, Chemical Engineering,
`Engineering, Pathology and Veterinary departments.
`Representatives from each department have, to date, been
`utilized in a peripheral manner to gain more knowledge
`and insight to bring about the project to its issuance. This
`working relationship will be needed to successfully
`complete this project.
`
`PROCEDURES
`
`. The project can be roughly divided into 3 phases. The
`first phase will be the successful assembly of working
`prototypes with subsequent fluid model testing. The
`second phase will be the placement of the devices into the
`pigs with subsequent data acquisition. The final stage will
`be the analysis of the data with subsequent conclusions.
`TIMELINE:
`
`1. PHASE 1
`
`2. PHASE 2
`
`3. PHASE 3
`
`8 TO 10 WEEKS
`
`1 TO 2 WEEKS
`
`6 TO 8 WEEKS
`
`NORRED EXHIBIT 2037 - Page 3
`
`
`
`
`
`This timeline may be influenced positively or negatively
`dependent upon initial successes/failures encountered at
`each stage.
`
`VI.
`
`DATA ACQUISITION
`
`. The most important data will be the initial success of
`placing the device without excess mortality in the pigs.
`Subsequently, we will collect data confirming the valves’
`function and durability through a variety of ways. These
`will include the use of the echo devices to precisely
`monitor the function of the valve in-vivo under a variety
`of stress conditions. Specifically, we will infuse
`vasopressors and chronotropic chemicals into the pigs to
`provide different rate and pressure situations and assess
`each devicesa tolerance to these conditions An
`
`intravascular ultrasound device will be utilized to assess
`
`the stent deployment within the ascending aorta, and a
`similar intracardiac echo will assess the coaptation of the
`aortic valves within the native aortic valve structure. This
`
`will provide crucial data as to the devicesi ability to open
`and close without impinging upon vital structures, namely,
`the coronary arteries. The hemodynamic equipment
`within the catheterization lab will be utilized to provide
`information as to the effect of deployment upon the pig’s
`circulatory system. These measurements will include
`instantaneous gradients across the valve and stent
`combination; along with standard measurements of cardiac
`output and systemic resistance. A hematologic profile
`will be collected from each valve to assess its rheostatic
`effects upon the circulating blood pool. In addition, fibrin
`assays will be drawn to assess the activation of the
`coagulation cascade. Cardiac enzymes will be
`periodically drawn to assess for microemholization or
`delayed trauma upon the cardiac circulation. Finally, the
`
`NORRED EXHIBIT 2037 - Page 4
`
`
`
`pigs will be sacrificed after these data have been collected,
`and tissue sections from the ascending aorta, heart, brain,
`lungs, kidneys, spleen and liver will be taken to assess for
`structural alterations which. may be related to the
`percutaneously delivered valves.
`
`VIl. FUTURE DIRECTlONS
`
`1., From this pilot study we will have the information needed
`to pursue more ambitious projects which will lead ultimately
`to trials in humans with inoperable aortic stenosis. From
`census data there were approximately 50 million Americans
`over the age of 65. Among this population there is an annual
`incidence of 2 to 9%, depending upon age, of aortic stenosis.
`This could mean that as high as 4.5 million elderly persons
`could suffer from this disease. Among those who are older,
`especially over 75, they are less likely to be operative
`candidates. This could represent a tremendous amount of
`patients who could be helped by this procedure. For the
`investor, this could represent a tremendous previously
`untapped market, Which could lead to substantial profits.
`For the physician, more importantly, it could lead to
`definitive treatment where previously there were few options
`besides palliation.
`i
`'
`
`NORRED EXHIBIT 2037 - Page 5
`
`
`
`Dizw\o§m5
`
`(kn: m~\¥:\nfim\\~) jflVnyS‘fi/S
`
`VQ\J%
`
`NORRED EXHIBIT 2037 - Page 6
`
`